Search - tctmd.com

Displaying 41 - 60 of 96

Sort: Relevancy | Date

Presentation

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

Presenter: Jose Carlos Nicolau

June 17, 2015

Presentation

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Presenter: Laurent Bonello

June 03, 2015

Presentation

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Presenter: Usman Baber

May 11, 2015

Presentation

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Presenter: J.M. Cubero

October 06, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation ESC 2014

Predictors of Bleeding in ACS Patients Treated With Prasugrel: Analysis From the ACCOAST Study

Presenter: Petr Widimsky

September 02, 2014

Presentation

In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients with AMI Treated with PCI

Presenter: Akshay Bagai

August 12, 2014

Presentation

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Presenter: J.A. Udell

June 17, 2014

Presentation

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

Presenter: Stefanie Schulz

May 14, 2014

Presentation

Onset of Antiplatelet Action with High (100 mg) vs Standard (60 mg) Loading Dose of Prasugrel in STEMI Patients Undergoing Primary PCI

Presenter: Dimitrios Alexopoulos

April 09, 2014

Presentation

INFUSE-AMI: Outcomes in Patients with STEMI Treated with Clopidogrel vs Prasugrel

Presenter: Sorin J. Brener

February 26, 2014

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Advertisement

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Predictors of Bleeding in ACS Patients Treated With Prasugrel: Analysis From the ACCOAST Study

In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients with AMI Treated with PCI

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

Onset of Antiplatelet Action with High (100 mg) vs Standard (60 mg) Loading Dose of Prasugrel in STEMI Patients Undergoing Primary PCI

INFUSE-AMI: Outcomes in Patients with STEMI Treated with Clopidogrel vs Prasugrel

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content